GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aratana Therapeutics Inc (NAS:PETX) » Definitions » Quick Ratio

Aratana Therapeutics (Aratana Therapeutics) Quick Ratio : 5.32 (As of Mar. 2019)


View and export this data going back to 2013. Start your Free Trial

What is Aratana Therapeutics Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Aratana Therapeutics's quick ratio for the quarter that ended in Mar. 2019 was 5.32.

Aratana Therapeutics has a quick ratio of 5.32. It generally indicates good short-term financial strength.

The historical rank and industry rank for Aratana Therapeutics's Quick Ratio or its related term are showing as below:

PETX's Quick Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 3.49
* Ranked among companies with meaningful Quick Ratio only.

Aratana Therapeutics Quick Ratio Historical Data

The historical data trend for Aratana Therapeutics's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aratana Therapeutics Quick Ratio Chart

Aratana Therapeutics Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Quick Ratio
Get a 7-Day Free Trial 10.51 15.43 2.61 2.02 8.40

Aratana Therapeutics Quarterly Data
Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.82 2.44 2.70 8.40 5.32

Competitive Comparison of Aratana Therapeutics's Quick Ratio

For the Biotechnology subindustry, Aratana Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aratana Therapeutics's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aratana Therapeutics's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Aratana Therapeutics's Quick Ratio falls into.



Aratana Therapeutics Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Aratana Therapeutics's Quick Ratio for the fiscal year that ended in Dec. 2018 is calculated as

Quick Ratio (A: Dec. 2018 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(58.127-11.425)/5.557
=8.40

Aratana Therapeutics's Quick Ratio for the quarter that ended in Mar. 2019 is calculated as

Quick Ratio (Q: Mar. 2019 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(53.922-10.828)/8.096
=5.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aratana Therapeutics  (NAS:PETX) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Aratana Therapeutics Quick Ratio Related Terms

Thank you for viewing the detailed overview of Aratana Therapeutics's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Aratana Therapeutics (Aratana Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
11400 Tomahawk Creek Parkway, Suite 340, Leawood, KS, USA, 66211
Aratana Therapeutics Inc is a pet therapeutics company. Its main activity is the licensing, developing, and commercializing of innovative biopharmaceutical products for companion animals. The company's portfolio consists of therapeutic candidates such as small-molecule pharmaceuticals and large-molecule biologics. The main product candidates in development comprise small-molecule pharmaceuticals directed at treating osteoarthritis pain, inflammation, appetite stimulation, and post-operative pain. The firm's strategy consists of licensing proprietary technology from human biopharmaceutical companies or academia to develop therapeutics specifically for use in pets.
Executives
Roche Robert P Jr director 41 MOORES ROAD FRAZER PA 19355
Vort John Vander director C/O MPM ASSET MANAGEMENT, 200 CLARENDON STREET 54TH FLOOR, BOSTON MA 02116
Lowell W Robinson director 470 WEST END AVENUE, NEW YORK NY 10024
Wendy L Yarno director
David L Brinkley director 901 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Merilee Raines director IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092
Kevin Kotler 10 percent owner C/O BROADFIN CAPITAL, LLC, 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Broadfin Capital, Llc 10 percent owner 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Broadfin Healthcare Master Fund Ltd 10 percent owner C/O 20 GENESIS CLOSE, ANSBACHER HOUSE, 2ND FLOOR, PO BOX 1344, GRAND CAYMAN E9 KY1-1108
Craig A. Barbarosh director 3525 PIEDMONT RD., NE, BUILDING 6, SUITE 700, ATLANTA GA 30305
Hockaday Irvine O Jr director SPRINT NEXTEL CORPORATION, 2001 EDMUND HALLEY DRIVE, RESTON VA 20191
Craig A Tooman director, officer: President and CEO
Peter Steven St director, officer: PRESIDENT AND CEO MPM CAPITAL, 200 CLARENDON STREET 54TH FLOOR, BOSTON MA 02116
Laura Brege director C/O ONYX PHARMACEUTICALS, INC., 2100 POWELL STREET, EMERYVILLE CA 94608
Jay Lichter director C/O ARATANA THERAPEUTICS, INC., 11400 TOMAHAWK CREEK PARKWAY, SUITE 340, LEAWOOD KS 66211